The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: The LIFE study

E. Fossum, G. W. Gleim, S. E. Kjeldsen, Jorge Kizer, S. Julius, R. B. Devereux, W. E. Brady, D. A. Hille, P. A. Lyle, B. Dahlöf

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objectives. Physical activity (PA) is a preventive strategy for cardiovascular disease and for managing cardiovascular risk factors. There is little information on the effectiveness of PA for the prevention of cardiovascular outcomes once cardiovascular disease is present. Thus, we studied the relationship between PA at baseline and cardiovascular events in a high-risk population. Design. A prespecified analyses of observational data in a prospective, randomized hypertension study. Setting. Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Subjects. Hypertension and left ventricular hypertrophy (LVH) (n = 9193). Interventions. Losartan versus atenolol. Main outcome measures. Reported level of PA: never exercise, exercise ≤30 min twice per week, or exercise >30 min twice per week at baseline and after a mean of 4.8 years of treatment with losartan- versus atenolol-based therapy. Risk reductions were calculated by level of PA for the primary composite end-point and its components cardiovascular death, stroke and myocardial infarction, and also all-cause mortality and new-onset diabetes. Results. A modest level of PA (>30 min twice per week) was associated with significant reductions in risk for the primary composite end-point [adjusted hazard ratio (aHR) 0.70, P < 0.001) and its components, all-cause mortality (aHR 0.65, P < 0.001), and new-onset diabetes (aHR 0.66, P < 0.001). Conclusion. A modest level of self-reported PA (>30 min twice per week) in patients with hypertension and LVH in the LIFE study was associated with significant reductions in risk for the primary composite end-point and its components of cardiovascular death, stroke, and myocardial infarction, all-cause mortality, and new-onset diabetes.

Original languageEnglish (US)
Pages (from-to)439-448
Number of pages10
JournalJournal of Internal Medicine
Volume262
Issue number4
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Left Ventricular Hypertrophy
Exercise
Hypertension
Losartan
Risk Reduction Behavior
Myocardial Infarction
Atenolol
Cardiovascular Diseases
Mortality
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Atenolol
  • Cardiovascular risk
  • Exercise
  • LIFE study
  • Losartan
  • Physical activity
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy : The LIFE study. / Fossum, E.; Gleim, G. W.; Kjeldsen, S. E.; Kizer, Jorge; Julius, S.; Devereux, R. B.; Brady, W. E.; Hille, D. A.; Lyle, P. A.; Dahlöf, B.

In: Journal of Internal Medicine, Vol. 262, No. 4, 10.2007, p. 439-448.

Research output: Contribution to journalArticle

Fossum, E. ; Gleim, G. W. ; Kjeldsen, S. E. ; Kizer, Jorge ; Julius, S. ; Devereux, R. B. ; Brady, W. E. ; Hille, D. A. ; Lyle, P. A. ; Dahlöf, B. / The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy : The LIFE study. In: Journal of Internal Medicine. 2007 ; Vol. 262, No. 4. pp. 439-448.
@article{b2f6e8959c3642e48fa63a3a566ad77b,
title = "The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: The LIFE study",
abstract = "Objectives. Physical activity (PA) is a preventive strategy for cardiovascular disease and for managing cardiovascular risk factors. There is little information on the effectiveness of PA for the prevention of cardiovascular outcomes once cardiovascular disease is present. Thus, we studied the relationship between PA at baseline and cardiovascular events in a high-risk population. Design. A prespecified analyses of observational data in a prospective, randomized hypertension study. Setting. Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Subjects. Hypertension and left ventricular hypertrophy (LVH) (n = 9193). Interventions. Losartan versus atenolol. Main outcome measures. Reported level of PA: never exercise, exercise ≤30 min twice per week, or exercise >30 min twice per week at baseline and after a mean of 4.8 years of treatment with losartan- versus atenolol-based therapy. Risk reductions were calculated by level of PA for the primary composite end-point and its components cardiovascular death, stroke and myocardial infarction, and also all-cause mortality and new-onset diabetes. Results. A modest level of PA (>30 min twice per week) was associated with significant reductions in risk for the primary composite end-point [adjusted hazard ratio (aHR) 0.70, P < 0.001) and its components, all-cause mortality (aHR 0.65, P < 0.001), and new-onset diabetes (aHR 0.66, P < 0.001). Conclusion. A modest level of self-reported PA (>30 min twice per week) in patients with hypertension and LVH in the LIFE study was associated with significant reductions in risk for the primary composite end-point and its components of cardiovascular death, stroke, and myocardial infarction, all-cause mortality, and new-onset diabetes.",
keywords = "Atenolol, Cardiovascular risk, Exercise, LIFE study, Losartan, Physical activity, Type 2 diabetes",
author = "E. Fossum and Gleim, {G. W.} and Kjeldsen, {S. E.} and Jorge Kizer and S. Julius and Devereux, {R. B.} and Brady, {W. E.} and Hille, {D. A.} and Lyle, {P. A.} and B. Dahl{\"o}f",
year = "2007",
month = "10",
doi = "10.1111/j.1365-2796.2007.01808.x",
language = "English (US)",
volume = "262",
pages = "439--448",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy

T2 - The LIFE study

AU - Fossum, E.

AU - Gleim, G. W.

AU - Kjeldsen, S. E.

AU - Kizer, Jorge

AU - Julius, S.

AU - Devereux, R. B.

AU - Brady, W. E.

AU - Hille, D. A.

AU - Lyle, P. A.

AU - Dahlöf, B.

PY - 2007/10

Y1 - 2007/10

N2 - Objectives. Physical activity (PA) is a preventive strategy for cardiovascular disease and for managing cardiovascular risk factors. There is little information on the effectiveness of PA for the prevention of cardiovascular outcomes once cardiovascular disease is present. Thus, we studied the relationship between PA at baseline and cardiovascular events in a high-risk population. Design. A prespecified analyses of observational data in a prospective, randomized hypertension study. Setting. Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Subjects. Hypertension and left ventricular hypertrophy (LVH) (n = 9193). Interventions. Losartan versus atenolol. Main outcome measures. Reported level of PA: never exercise, exercise ≤30 min twice per week, or exercise >30 min twice per week at baseline and after a mean of 4.8 years of treatment with losartan- versus atenolol-based therapy. Risk reductions were calculated by level of PA for the primary composite end-point and its components cardiovascular death, stroke and myocardial infarction, and also all-cause mortality and new-onset diabetes. Results. A modest level of PA (>30 min twice per week) was associated with significant reductions in risk for the primary composite end-point [adjusted hazard ratio (aHR) 0.70, P < 0.001) and its components, all-cause mortality (aHR 0.65, P < 0.001), and new-onset diabetes (aHR 0.66, P < 0.001). Conclusion. A modest level of self-reported PA (>30 min twice per week) in patients with hypertension and LVH in the LIFE study was associated with significant reductions in risk for the primary composite end-point and its components of cardiovascular death, stroke, and myocardial infarction, all-cause mortality, and new-onset diabetes.

AB - Objectives. Physical activity (PA) is a preventive strategy for cardiovascular disease and for managing cardiovascular risk factors. There is little information on the effectiveness of PA for the prevention of cardiovascular outcomes once cardiovascular disease is present. Thus, we studied the relationship between PA at baseline and cardiovascular events in a high-risk population. Design. A prespecified analyses of observational data in a prospective, randomized hypertension study. Setting. Losartan Intervention For Endpoint reduction in hypertension (LIFE) study Subjects. Hypertension and left ventricular hypertrophy (LVH) (n = 9193). Interventions. Losartan versus atenolol. Main outcome measures. Reported level of PA: never exercise, exercise ≤30 min twice per week, or exercise >30 min twice per week at baseline and after a mean of 4.8 years of treatment with losartan- versus atenolol-based therapy. Risk reductions were calculated by level of PA for the primary composite end-point and its components cardiovascular death, stroke and myocardial infarction, and also all-cause mortality and new-onset diabetes. Results. A modest level of PA (>30 min twice per week) was associated with significant reductions in risk for the primary composite end-point [adjusted hazard ratio (aHR) 0.70, P < 0.001) and its components, all-cause mortality (aHR 0.65, P < 0.001), and new-onset diabetes (aHR 0.66, P < 0.001). Conclusion. A modest level of self-reported PA (>30 min twice per week) in patients with hypertension and LVH in the LIFE study was associated with significant reductions in risk for the primary composite end-point and its components of cardiovascular death, stroke, and myocardial infarction, all-cause mortality, and new-onset diabetes.

KW - Atenolol

KW - Cardiovascular risk

KW - Exercise

KW - LIFE study

KW - Losartan

KW - Physical activity

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=34548613040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548613040&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2796.2007.01808.x

DO - 10.1111/j.1365-2796.2007.01808.x

M3 - Article

C2 - 17875180

AN - SCOPUS:34548613040

VL - 262

SP - 439

EP - 448

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 4

ER -